Cetuximab Recruiting Phase 2 Trials for Neoplasms, Head and Neck / Metastatic Cancers / Recurrent Head and Neck Cancer / Head and Neck Carcinoma Treatment

IndicationsStatusPurposePhase
RecruitingTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT03691714Durvalumab (MEDI4736) With Cetuximab in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
NCT01020864Cetuximab in Combination With Chemotherapy for Patients With Head and Neck Cancer